Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
This activity is supported by an educational grant from AstraZeneca.
February 2022
The Interferon Gene Signature as a Clinically Relevant Biomarker in Autoimmune Rheumatic Disease
Lancet Rheumatol 2022;4:e61–72.
The interferon gene signature (IGS) fits into the paradigm of a personalised approach to care in rheumatic diseases, where an individual’s score could inform either prompt diagnosis, early use of certain therapies, or presage specific clinical phenotypes.
Flares after Hydroxychloroquine Reduction or Discontinuation: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Ann Rheum Dis. 2021:annrheumdis-2021-221295. Epub ahead of print
Evidence suggests that hydroxychloroquine (HCQ) reduction/withdrawal may be safe in some stable patients, but in other settings it may be associated with disease flare. Almeida-Brasil, et al. sought to evaluate SLE flares following HCQ reduction or discontinuation versus HCQ maintenance. Their data suggest that maintaining HCQ was associated with a lower flare risk than reduction or discontinuation, even in patients with low disease activity or remission.
January 2022
Efficacy and Safety of Ustekinumab in Patients with Active Systemic Lupus Erythematosus: Results Through 2 Years of an Open-Label Extension in a Phase 2 Study
J Rheumatol. 2021. Epub ahead of print
Phase II data demonstrate clinical benefit in global and organ-specific SLE-activity measures with ustekinumab through 2 years with no new or unexpected safety findings.
2019-EULAR/ACR Classification Criteria Domains at Diagnosis: Predictive Factors of Long-Term Damage In Systemic Lupus Erythematosus
Clin Rheumatol. 2021. Epub ahead of print
Single-centre, retrospective analysis identifying that specific domains in the 2019-EULAR/ACR criteria at diagnosis are associated with long-term organ-specific damage, particularly renal and neuropsychiatric harm.